[go: up one dir, main page]

GB201617622D0 - Means and methods to treat inflammation - Google Patents

Means and methods to treat inflammation

Info

Publication number
GB201617622D0
GB201617622D0 GBGB1617622.4A GB201617622A GB201617622D0 GB 201617622 D0 GB201617622 D0 GB 201617622D0 GB 201617622 A GB201617622 A GB 201617622A GB 201617622 D0 GB201617622 D0 GB 201617622D0
Authority
GB
United Kingdom
Prior art keywords
methods
treat inflammation
inflammation
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1617622.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VIB VZW and Universiteit Gent
Original Assignee
VIB VZW and Universiteit Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VIB VZW and Universiteit Gent filed Critical VIB VZW and Universiteit Gent
Priority to GBGB1617622.4A priority Critical patent/GB201617622D0/en
Publication of GB201617622D0 publication Critical patent/GB201617622D0/en
Priority to PCT/EP2017/076427 priority patent/WO2018073216A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB1617622.4A 2016-10-18 2016-10-18 Means and methods to treat inflammation Ceased GB201617622D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1617622.4A GB201617622D0 (en) 2016-10-18 2016-10-18 Means and methods to treat inflammation
PCT/EP2017/076427 WO2018073216A1 (en) 2016-10-18 2017-10-17 Means and methods to treat inflammation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1617622.4A GB201617622D0 (en) 2016-10-18 2016-10-18 Means and methods to treat inflammation

Publications (1)

Publication Number Publication Date
GB201617622D0 true GB201617622D0 (en) 2016-11-30

Family

ID=57680868

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1617622.4A Ceased GB201617622D0 (en) 2016-10-18 2016-10-18 Means and methods to treat inflammation

Country Status (2)

Country Link
GB (1) GB201617622D0 (en)
WO (1) WO2018073216A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250005464A (en) 2017-06-02 2025-01-09 메르크 파텐트 게엠베하 Polypeptides binding adamts5, mmp13 and aggrecan
US12129308B2 (en) * 2017-06-02 2024-10-29 Merck Patent Gmbh MMP13 binding immunoglobulins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089843A1 (en) * 2001-03-13 2002-11-14 Millenium Pharmaceuticals, Inc. Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function
US9028822B2 (en) * 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
ATE514714T1 (en) * 2007-03-19 2011-07-15 Univ Stuttgart HUTNFR1 SELECTIVE ANTAGONISTS
MX2009013137A (en) * 2007-06-06 2010-04-30 Domantis Ltd Methods for selecting protease resistant polypeptides.
GB201018602D0 (en) * 2010-11-04 2010-12-22 Vib Vzw MMP8 inactivating antigen binding proteins
US9403891B2 (en) * 2011-03-10 2016-08-02 New York University Methods and compositions for modulating TNF/TNFR signaling

Also Published As

Publication number Publication date
WO2018073216A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
IL255780A (en) Therapeutic combinations and methods for treating neoplasia
IL259570A (en) Combination treatments and uses and methods thereof
IL249292B (en) Methods and devices for treating pulmonary edema
ZA201607540B (en) Compositions and methods to treating hemoglobinopathies
SG11201802794PA (en) Therapeutic compounds and methods
EP3151797A4 (en) Methods and devices for treating the skin
AP2017009674A0 (en) Methods and compositions for treating ulcers
IL251759B (en) Preparations and methods for treating insomnia
PT3189074T (en) Compositions and methods for treating and preventing inflammation
EP2993160A4 (en) Water treatment device and water treatment method
PT3448516T (en) Phototherapy apparatuses and methods
ZA201701571B (en) Water treatment system and method
SG11201704477VA (en) Power system and method
SG11201510300RA (en) Compositions and methods for treating skin
PL2993159T3 (en) Water treatment device and water treatment method
EP3093055A4 (en) Water treatment device and water treatment method
IL250114A0 (en) Methods and compositions for treating hiv-related disorders
GB201617622D0 (en) Means and methods to treat inflammation
EP3523433C0 (en) Means and methods to treat inflammatory diseases
IL252070A0 (en) Apoaequorin-containing compositions and methods of using same to treat neuronal inflammation
IL255012A0 (en) Compositopns and methods for treating skin conditions
EP3159055A4 (en) Water treatment method and water treatment device
EP3119307A4 (en) Skin treatment devices and methods
GB201513590D0 (en) Devices and methods
IL250244B (en) Preventing and treating inflammatory skin diseases

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)